CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a
clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare
diseases, today announced that Idera’s Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will provide a corporate overview and
update at the 37th Annual Cowen and Company Health Care Conference on Wednesday, March 8, 2017 at 11:20 a.m. Eastern
Time at the Boston Marriott Copley Place.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s
website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment
of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic
oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera
has created a third generation antisense technology platform using its proprietary technology to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) rdoody@iderapharma.com